Abstract The American Medical Association recently recognized obesity as both an illness
and a leading cause of preventable death and chronic disease. This association is not only …

BackgroundIt is unclear what the prevalence of metabolic syndrome (MetS) in drug-naïve
first-episode of psychosis (FEP) is, as previous meta-analyses were conducted in minimally …

Background Omega-3 fatty acids, in particular, eicosapentaenoic acid (EPA) have been
suggested as augmentation strategies in the treatment of schizophrenia and related …

To review the data with respect to prevalence of metabolic syndrome (MetS) and its
correlates in schizophrenia. For this review, electronic search engines PUBMED …

Aim: There is an increasing recognition of the impact of weight gain on the development of
metabolic abnormalities in young people receiving atypical antipsychotic drugs for first …

Aim: The article aims to study the prevalence of metabolic syndrome (MS) and subthreshold
MS in antipsychotic naïve patients with schizophrenia. Materials and methods: Forty‐six …

Despite the call by the scientific community for a systematic monitoring of physical health in
people with psychiatric illnesses, national and international audits have reported poor …

Aim This study aimed to assess the prevalence of metabolic syndrome (MS) and
subthreshold MS in antipsychotic naïve patients with schizophrenia by pooling the data from …

Background: Persons with severe mental illness are at relatively greater risk of developing
obesity, type 2 diabetes mellitus, hypertension, and dyslipidemia as compared to the normal …